Correction to COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.

Autor: Kowdley KV; Liver Institute Northwest and Elson S. Floyd College of Medicine, Washington State University, Seattle, Washington, USA., Hirschfield GM; Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Coombs C; Real World Evidence, Syneos Health, Morrisville, North Carolina, USA., Malecha ES; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Bessonova L; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Li J; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Rathnayaka N; Department of Population Health Sciences, Duke University, Durham, North Carolina, USA., Mells G; Cambridge University Hospitals NHS Foundation Trust MRC Clinical Academic Research Partner, Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK., Jones DE; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK., Trivedi PJ; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Hansen BE; Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands.; IHPME University of Toronto, Toronto, Ontario, Canada.; Toronto Centre for Liver Disease and TGHRI, University Health Network, Toronto, Ontario, Canada., Smith R; Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Wason J; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK., Hiu S; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK., Kareithi DN; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK., Mason AL; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada., Bowlus CL; University of California Davis, Sacramento, California, USA., Muller K; Flinders Medical Centre, Adelaide, South Australia, Australia., Carbone M; University of Milano-Bicocca, Milano, Italy., Berenguer M; La Fe University Hospital, IISLaFe, Ciberehd, University of Valencia, Valencia, Spain., Milkiewicz P; Medical University of Warsaw, Warszawa, Poland.; Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland., Adekunle F; Intercept Pharmaceuticals, London, UK., Villamil A; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Publikováno v: The American journal of gastroenterology [Am J Gastroenterol] 2024 Nov 29. Date of Electronic Publication: 2024 Nov 29.

Anti-integrin αvβ6 Autoantibodies are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity.

Autor: Bloemen H; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Livanos AE; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: alexandra.livanos@mountsinai.org., Martins A; Schiff Center for Liver Diseases, University of Miami Leonard M. Miller School of Medicine, Miami, Florida., Dean R; Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California., Bravo AC; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal., Bourgonje AR; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Tankelevich M; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Herb J; The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Cho J; The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Santos AA; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal., Rodrigues CMP; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal., Petralia F; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York., Colombel JF; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Bowlus CL; Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California., Schiano T; Recanati/Miller Transplantation Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Torres J; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal; Faculty of Medicine, Universidade de Lisboa, Lisbon, Portugal; Division of Gastroenterology, Hospital da Luz, Lisbon, Portugal., Levy C; Schiff Center for Liver Diseases, University of Miami Leonard M. Miller School of Medicine, Miami, Florida; Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: clevy@med.miami.edu., Mehandru S; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: saurabh.mehandru@mssm.edu.

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2024 Oct 25. Date of Electronic Publication: 2024 Oct 25.

COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.

Autor: Kowdley KV; Liver Institute Northwest and Elson S. Floyd College of Medicine, Washington State University, Seattle, Washington, USA., Hirschfield GM; Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada., Coombs C; Real World Evidence, Syneos Health, Morrisville, North Carolina, USA., Malecha ES; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Bessonova L; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Li J; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Rathnayaka N; Department of Population Health Sciences, Duke University, Durham, North Carolina, USA., Mells G; Cambridge University Hospitals NHS Foundation Trust MRC Clinical Academic Research Partner, Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK., Jones DE; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK., Trivedi PJ; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Hansen BE; Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands.; IHPME University of Toronto, Toronto, Ontario, Canada.; Toronto Centre for Liver Disease and TGHRI, University Health Network, Toronto, Ontario, Canada., Smith R; Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Wason J; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK., Hiu S; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK., Kareithi DN; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK., Mason AL; Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada., Bowlus CL; University of California Davis, Sacramento, California, USA., Muller K; Flinders Medical Centre, Adelaide, South Australia, Australia., Carbone M; University of Milano-Bicocca, Milano, Italy., Berenguer M; La Fe University Hospital, IISLaFe, Ciberehd, University of Valencia, Valencia, Spain., Milkiewicz P; Medical University of Warsaw, Warszawa, Poland.; Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland., Adekunle F; Intercept Pharmaceuticals, London, UK., Villamil A; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Publikováno v: The American journal of gastroenterology [Am J Gastroenterol] 2024 Aug 14. Date of Electronic Publication: 2024 Aug 14.

Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.

Autor: Kremer AE; Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland., Mayo MJ; Division of Digestive and Liver Diseases, University of Texas SW Medical Center, Dallas, Texas, USA., Hirschfield GM; Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada., Levy C; Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.; Schiff Center for Liver Diseases, University of Miami, Miami, Florida, USA., Bowlus CL; Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of California Davis, Sacramento, California, USA., Jones DE; Clinical and Translation Research Institute, Newcastle University, Newcastle upon Tyne, UK., Johnson JD; CymaBay Therapeutics, Inc., Fremont, California, USA., McWherter CA; CymaBay Therapeutics, Inc., Fremont, California, USA., Choi YJ; CymaBay Therapeutics, Inc., Fremont, California, USA.

Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2024 Jul 01; Vol. 80 (1), pp. 27-37. Date of Electronic Publication: 2023 Dec 20.

Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trials.

Autor: Li M; Department of Medicine, Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA., Pai RA; PSC Partners Seeking a Cure, Greenwood Village, Colorado, USA., Gomel R; PSC Partners Seeking a Cure, Greenwood Village, Colorado, USA., Vyas M; PSC Partners Seeking a Cure Canada, Toronto, ON, Canada., Callif SC; PSC Partners Seeking a Cure, Greenwood Village, Colorado, USA., Hatchett J; PSC Partners Seeking a Cure, Greenwood Village, Colorado, USA., Bowlus CL; Department of Medicine, Division of Gastroenterology and Hepatology, University of California Davis Health, Sacramento, California, USA., Lai JC; Department of Medicine, Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA.

Publikováno v: Hepatology communications [Hepatol Commun] 2024 May 10; Vol. 8 (6). Date of Electronic Publication: 2024 May 10 (Print Publication: 2024).